Inhibikase Therapeutics, Inc. (IKT) Operating Lease, Liability USD 2022 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Present value of lessee's discounted obligation for lease payments from operating lease.
Summary
Inhibikase Therapeutics, Inc. quarterly Operating Lease, Liability history and growth rate from 2022 to 2024.
  • Inhibikase Therapeutics, Inc. Operating Lease, Liability for the quarter ending March 31, 2024 was $209 K, a 35.5% decline year-over-year.
Operating Lease, Liability, Quarterly (USD)
Operating Lease, Liability, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $209 K -$116 K -35.5% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $240 K -$111 K -31.6% Dec 31, 2023 10-K 2024-03-27
Q3 2023 $270 K -$104 K -27.8% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $298 K Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $325 K Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $351 K Dec 31, 2022 10-K 2023-03-31
Q3 2022 $374 K Sep 30, 2022 10-Q 2022-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.